Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes

Nature Medicine

Volumn 7, Issue 11, 2001, Pages 1225-1231

  Chen, Xueni ^a   Scala, Giuseppe ^a,b,c   Quinto, Ileana ^a,b,c   Liu, Weimin ^a   Chun, Tae Wook ^a   Shawn Justement, J ^a   Cohen, Oren J ^a   Vancott, Tom C ^d   Iwanicki, Marcin ^d   Lewis, Mark G ^e   Greenhouse, Jack ^e   Barry, Todd ^f   Venzon, David ^f   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d 3Henry M Jackson Foundation   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS ISOLATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; EPITOPES; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; PEPTIDE LIBRARY; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035175383     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1101-1225     Document Type: Article

References (44)

1. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
2. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
3. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
4. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
5. Clinical implications of basic research: Antibodies and resistance to natural HIV infection
6. Human retroviruses and AIDS
7. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
8. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41
9. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
10. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
11. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
12. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 participating in trials of recombinant gp120 subunit vaccines
13. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
14. Selection of biologically active peptides by phage display of random peptide libraries
15. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics
16. A role for carbohydrates in immune evasion in AIDS
17. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera
18. Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens
19. Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. The V3 loop of HIV- 1 gp120
20. + T cell function in vivo in HIV-infected patients as measured by bacteriophage φX 174 immunization
21. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses
22. Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor
23. HIV-1 heterogeneity and cytokines. Neuropathogenesis
24. Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
25. The antigenic structure of the HIV gp 120 envelope glycoprotein
26. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate
27. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
28. Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV
29. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
30. + lymphocyte depletion in rhesus monkeys
31. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
32. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
33. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
34. + T cells: Implications for the development of therapeutic strategies
35. Membranous glomerutonephritis
36. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
37. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
38. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
39. Viral load and heterosexual transmission of human immunodeficiency virus type 1
40. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
41. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine
42. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp 120 and oligomeric gp140
43. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control
44. HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992- 1996